Pediatric exclusivity is an additional six months of market protection granted to drug manufacturers who voluntarily conduct and submit studies on the safety, efficacy, and appropriate dosing for children. This incentive is part of the BPCA and aims to encourage the development of more medications that are safe and effective for pediatric use. This six-month extension is added to any existing exclusivity or patent protection the drug already has.